{"filing":{"accession_number":"0001104659-26-093066","cik":"0001583107","ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"tm2622638d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926093066/tm2622638d1_8k.htm"},"events":[{"id":26419,"run_id":24011,"accession_number":"0001104659-26-093066","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 disclosing financial results including revenue of $20.7 million, net loss of $5.9 million, and cash position of $387.7 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. While the filing also mentions the pending Zymeworks acquisition, the primary content and structure of this Item 2.02 disclosure is the quarterly financial results presentation.","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27538,"accession_number":"0001104659-26-093066","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results including revenue of $20.7 million, net loss of $5.9 million, and cash position of $387.7 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. While the filing also mentions the pending Zymeworks acquisition, the primary content and structure of this Item 2.02 disclosure is the quarterly financial results presentation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:36:56.108997+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27538,"accession_number":"0001104659-26-093066","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results including revenue of $20.7 million, net loss of $5.9 million, and cash position of $387.7 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. While the filing also mentions the pending Zymeworks acquisition, the primary content and structure of this Item 2.02 disclosure is the quarterly financial results presentation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:36:56.108997+00:00","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-08-10"}]}